Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Rhea-AI Summary

Argus Aug 27 session 1 alert

-2.08% close to close 2.0x rel. volume Open Argus

Details

News Market Reaction – LNAI

$11.33M Market Cap

On Aug 27, the day this news came out, LNAI closed 2.08% below the previous close. Relative volume reached 2.0x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 27 session.

Key Figures

Broker-dealers named: 6 registered broker-dealers Broker-dealer principals named: 2 broker-dealer principals Filing date: Aug. 27, 2026 +2 more

Broker-dealers named

6 registered broker-dealers

Second Amended Complaint

Broker-dealer principals named

2 broker-dealer principals

Named as defendants for the first time

Filing date

Aug. 27, 2026

Second Amended Complaint

Civil action number

26-549-CFC

U.S. District Court for the District of Delaware

Legal rule

Rule 10b-5

Securities fraud and market manipulation allegations

Historical Context

5 past events · Latest: Aug 04

5 events

1. Aug 04

   Collaboration agreement

   24h Move

   +6.7%

   BrainStorm collaboration targeted an initial Parkinson's disease data readout in first-half 2027.

2. Aug 04

   Naked short-selling suit

   24h Move

   +6.7%

   Company named 10 defendants in a naked short-selling fraud lawsuit.

3. Jun 17

   Shareholder progress letter

   24h Move

   +40.6%

   CEO cited a defense contract, platform progress, and renewed Nasdaq compliance.

4. May 28

   Neurology collaboration

   24h Move

   +16.0%

   Foundation-funded collaboration pursued AI-enabled Parkinson's and epilepsy target discovery.

5. May 22

   Expedited discovery order

   24h Move

   -2.6%

   Federal judge ordered expedited discovery to identify alleged naked short-sellers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rule 10b-5, broker-dealers, naked short selling

3 terms

rule 10b-5 regulatory

"Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5"

A U.S. securities rule that makes it illegal to lie, omit important facts, or use deceptive practices when buying or selling stocks and other securities. Think of it as a sports referee rule that keeps the playing field fair: investors rely on truthful information to decide whether to buy or sell, and violations can lead to lawsuits, fines, or forced returns of profits, which can affect a company’s stock price and investor confidence.

broker-dealers financial

"naming six registered broker-dealers and two broker-dealer principals"

A broker-dealer is a firm or individual that helps people buy and sell securities and may also trade those securities for its own account. Think of it like a market clerk who can either match a buyer with a seller or sell items from the shop’s shelves; investors rely on broker-dealers to execute trades, custody assets, provide market access and advice, and their actions and fees can affect trade speed, cost and potential conflicts of interest.

naked short selling financial

"Lunai Bioworks Names Six Broker-Dealers in Expanded Naked Short Selling Suit"

Naked short selling is selling shares you do not own and have not borrowed or reserved to deliver to the buyer, unlike ordinary short selling where the seller first borrows the shares. Think of it as promising to sell a car you haven’t secured from a lender or owner; if the seller can’t deliver, it can artificially increase the number of shares trading, push the price down, and raise risks for investors and for the company’s market stability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 27, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC).

A copy of the Second Amended Complaint is available at https://bit.ly/45Q1MLE.

About Lunai Bioworks, Inc.

Lunai Bioworks, Inc. (Nasdaq: LNAI) is a Delaware corporation headquartered in Sacramento, California. Lunai is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company has developed a cancer immunotherapy for solid tumors and proprietary, patented technologies that transform complex biomedical data into predictive insights. Lunai's platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts in support of national security and biodefense applications through its AI platform. For more information, visit www.biosymetrics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Lunai's litigation strategy, its expectations regarding the identification of additional defendants, and the anticipated outcome or recovery from the lawsuit described herein. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks inherent in civil litigation, the possibility that discovery does not develop as anticipated, that courts may not accept the legal theories advanced, that named defendants may contest the allegations, and that any recovery, if obtained, may differ materially from the amounts or outcomes described or implied in this release. The allegations described in this release are allegations only and have not been proven; defendants are presumed to have meritorious defenses unless and until a court or jury determines otherwise. Lunai undertakes no obligation to update these statements except as required by law. Investors should review Lunai's filings with the Securities and Exchange Commission for a further discussion of these and other risks.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-nasdaq-lnai-names-six-broker-dealers-in-expanded-naked-short-selling-suit-302861870.html

SOURCE Lunai Bioworks Inc.